KEYNOTE-716
Extended adjuvant immunotherapy to thick node-negative melanomas, a group whose risk of relapse rivals stage III.
RFS and distant metastasis-free survival improved (FDA approval December 2021 for stage IIB/IIC). Five-year follow-up (ESMO 2025) reported sustained RFS and DMFS benefit; OS not yet mature. The absolute benefit is smaller than in stage III and the trial reignited debate about over-treatment given that most stage II patients never relapse.
Pages like this
not linked directly; found by shared links- PairingPD-1 failure → TIL therapy
Shares Pembrolizumab, Melanoma.
- TrialKEYNOTE-006
Shares Pembrolizumab, Melanoma.
- TrialKEYNOTE-689
Shares Event-free / disease-free survival (EFS, DFS, iDFS, RFS), Pembrolizumab.
- TrialINTerpath-001 (V940-001)
Shares Event-free / disease-free survival (EFS, DFS, iDFS, RFS), Pembrolizumab, Melanoma.
- IdeaRandomise a cheap antihistamine alongside immunotherapy
Shares Pembrolizumab, Melanoma.
- TrialSWOG S1801
Shares Pembrolizumab, Melanoma.
- PersonAlexander Eggermont
Shares Pembrolizumab, Melanoma.
- TrialTROPION-Breast03
Shares Event-free / disease-free survival (EFS, DFS, iDFS, RFS), Pembrolizumab.